Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide in gallbladder cancer, run by Beijing Biotech, now recruiting.
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT07641036 by Beijing Biotech, with 30 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide. Conditions listed: Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/